Keywords: medarex, 1st-qtr, sales, soar, loss, grows, new
Medarex' 1st-qtr sales soar, but loss grows
Article | 30 May 2005
New Jersey, USA-headquartered biopharmaceutical group Medarex, which focuses on the development of antibody-based therapeutics, has reported a steep increase in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
